In a cross-sectional analysis of 136 patients from the Eplerenone in Primary Hyperparathyroidism (EPATH) trial, investigators evaluated the association between inflammatory biomarkers—including CRP, KYN, quinolinic acid (QUIN), and TRP—and echocardiographic indicators of adverse cardiac remodeling. The gene discussed is CRP; the disease is primary hyperparathyroidism.